Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.

Kahn Swick & Foti is investigating Lantheus Holdings' proposed sale to Curium US Holdings. The transaction offers Lantheus shareholders $102.50 per share in cash plus non-transferable contingent value rights worth up to an additional $12.00 per share, implying maximum potential consideration of $114.50 per share. The legal review introduces deal-execution uncertainty, although the announced cash consideration is supportive for Lantheus shareholders.

Analysis

This is merger-arbitrage, not a fundamental re-rating signal. A plaintiff-law-firm investigation is routine after public-company transactions and, absent a competing bid, regulatory objection, or a disclosed process defect, should have little bearing on closing probability. The relevant market variable is LNTH's discount to the cash consideration plus the market-implied value of the CVR; the CVR's non-transferability and contingent structure warrant a substantial haircut rather than being treated as cash-equivalent consideration.

Near term, any widening in the LNTH spread driven solely by this notice is potentially buyable, but only after confirming the transaction's antitrust path, financing certainty, expected closing date, and CVR milestone definitions. Over 1-3 months, the principal upside is spread compression as merger filings and shareholder approval progress; downside is materially asymmetric if the deal breaks because standalone LNTH would likely trade on its nuclear-medicine growth outlook, reimbursement exposure, and competitive intensity rather than the deal price. A higher Curium bid is possible but should not be underwritten without evidence of another strategic or financial sponsor in the process.

The contrarian point is that the headline may create an unjustified litigation overhang while ignoring CVR valuation. If the common stock trades near $102.50, investors are effectively receiving limited expected value for a long-dated, illiquid CVR and should not chase the nominal $114.50 maximum. Conversely, a spread implying a low closing probability despite clean regulatory signals would offer a more attractive risk-adjusted entry than a bet on litigation extracting incremental consideration.

Key Decisions for Investors

• Watch LNTH versus the $102.50 cash leg daily; consider a small merger-arb long only if the annualized gross spread exceeds approximately 10-12% after incorporating the announced expected close date and a conservative zero-to-low value for the CVR.
• Do not assign more than a modest probability-weighted value to the CVR until the definitive merger proxy identifies each payment trigger, measurement period, payer credit support, and whether milestones are within Curium's operational control.
• Use merger-agreement filing, HSR/other regulatory clearances, financing disclosures, and the shareholder-vote date as 1-3 month catalysts for spread compression; reduce or exit if regulatory review extends unexpectedly or if Curium financing conditions appear conditional.
• Risk-manage the long with a hard review trigger on any material downward revision to LNTH standalone guidance or a transaction-process disclosure suggesting a credible superior-bid issue; these events alter break-price and closing-probability assumptions.
• Avoid shorting sector peers as a hedge: LNTH-specific deal risk is unlikely to transmit cleanly to PET imaging or radiopharmaceutical comparables, making cash/T-bill financing or position-size discipline preferable to an imprecise beta hedge.